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It is now 18 years since the ﬁrst identiﬁcation of a case of
vCJD in the UK. Since that time, there has been much
speculation over how vCJD might impact human health. To
date there have been 177 case reports in the UK and a further
51 cases worldwide in 11 different countries. Since
establishing that BSE and vCJD are of the same strain of
agent, we have also shown that there is broad similarity
between UK and non-UK vCJD cases on ﬁrst passage to mice.
Transgenic mouse studies have indicated that all codon 129
genotypes are susceptible to vCJD and that genotype
may inﬂuence whether disease appears in a clinical or
asymptomatic form, supported by the appearance of the ﬁrst
case of potential asymptomatic vCJD infection in a PRNP
129MV patient. Following evidence of blood transfusion as a
route of transmission, we have ascertained that all blood
components and leucoreduced blood in a sheep model of
vCJD have the ability to transmit disease. Importantly, we
recently established that a PRNP 129MV patient blood
recipient with an asymptomatic infection and limited PrPSc
deposition in the spleen could readily transmit disease into
mice, demonstrating the potential for peripheral infection in
the absence of clinical disease. This, along with the recent
appendix survey which identiﬁed 16 positive appendices
in a study of 32 441 cases, underlines the importance of
continued CJD surveillance and maintaining control measures
already in place to protect human health.
Introduction
Transmissible spongiform encephalopathies (TSE) or prion
diseases are a unique group of fatal neurodegenerative diseases
occurring in humans and mammals. Prion diseases can be spo-
radic, heritable, or acquired, they can be transmitted both natu-
rally and experimentally, and as yet, there is no known cure. In
1996, an acquired human prion disease, variant Creutzfeldt–
Jakob disease (vCJD), was described in the United Kingdom
(UK) leading to a flurry of news reports, changes in government
policies regarding the beef industry, a ban on exports of meat,
restrictions on blood donations and a widespread fear that any-
one could be infected. Since that first report, researchers and
health professionals have endeavored to try and understand the
disease, identify the infectious agent, assess transmission risks and
ultimately improve diagnosis and find a cure. This review will
summarize 18 y of research from identification of disease strain,
epidemiology, and genetics, to assessing risks of transmission,
diagnosis, and therapeutics, and finally the current issues of sub-
clinical disease and ongoing surveillance.
BSE and vCJD: The Same Strain of Agent
In 1985, a novel neurodegenerative disease of cattle was recog-
nized in the UK. Pathological examination of the brain material
from these cattle suggested that this was a new TSE subsequently
named bovine spongiform encephalopathy (BSE).1 A further exami-
nation of these cases was performed following transmission of brain
material to a panel of wild-type mice. The RIII, C57BL, and VM
mice gave similar incubation periods, rankings, and vacuolation pro-
files for each isolate. Vacuolation distribution in the Prnp-a mice
(RIII and C57BL) show distinctive profiles with higher levels or
“peak” of vacuolation in the dorsal medulla, hypothalamus, and sep-
tum (Fig. 1) whereas Prnp-b mice (VM) show peaks in the dorsal
medulla, superior colliculus, thalamus, and septum.2 This BSE sig-
nature was confirmed in a number of cases of BSE and was observed
in a number of similar transmissions from cats,3 kudu, and nyala.4
© Abigail B Diack, Mark W Head, Sandra McCutcheon, Aileen Boyle, Richard
Knight, James W Ironside, Jean C Manson, and Robert G Will
*Correspondence to: Jean C Manson; Email: jean.manson@roslin.ed.ac.uk
Submitted: 03/17/2014; Revised: 05/02/2014; Accepted: 05/14/2014
http://dx.doi.org/10.4161/pri.29237
This is an Open Access article distributed under the terms of the Creative
Commons Attribution-Non-Commercial License (http://creativecommons.
org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use,
distribution, and reproduction in any medium, provided the original work is
properly cited. The moral rights of the named author(s) have been asserted.
286 Volume 8 Issue 4Prion
Prion 8:4, 286--295; July/August 2014; Published with license by Taylor & Francis Group, LLC
REVIEW
D
ow
nl
oa
de
d 
by
 [T
he
 U
niv
ers
ity
 of
 E
din
bu
rg
h]
 at
 06
:47
 19
 D
ec
em
be
r 2
01
4 
Thus confirming a single agent was responsible for these new TSE
cases in each species. Furthermore this agent was experimentally
transmitted to sheep and goats.5
Ten years after BSE was recognized, the first case of an atypi-
cal form of Creutzfeldt–Jakob disease, termed “new variant
CJD” (vCJD) in humans was identified;6 both diseases were rec-
ognized to be prion diseases, raising serious concerns that BSE
had now spread to humans via consumption of infected meat
products.7 Following the same protocols that had been used for
the animal transmissions, a series of vCJD transmissions were
set up. Initial results published in 1997 using RIII mice indi-
cated that vCJD was indeed caused by the BSE agent.8 At the
same time, Hill et al.9 showed similar results using FVB mice.
Further studies have shown that incubation period rankings,
lesion profiles and abnormal prion protein (PrPSc) deposition
patterns are all identical to the BSE agent (Figs. 1 and 2).10,11
The definitive evidence that BSE and vCJD were the same
strain came with the characterization of primary and secondary
transmission of 10 cases of vCJD to mice. In this study both
CNS and peripheral material was transmitted and showed that
in all cases transmission characteristics were similar to BSE.12
To date, all cases of UK 129MM (methionine homozygous)
vCJD that have been characterized have shown similar strain
characteristics to BSE.
In addition to epidemiological, neuropathological, and bio-
logical evidence, the biochemical analysis of PrPSc deposited in
both the BSE brain and vCJD brain also supports a link between
the agents responsible. Western blotting of partially protease-
resistant prion protein provides a surrogate for conformation
and/or aggregation state and also reflects glycosylation site occu-
pancy in the form of (generally 3) bands of protease-resistant
prion protein (PrPres) of defined mobility (determined by N-ter-
minal truncation) and relative abundance (determined by glyco-
sylation). Using this method BSE can be differentiated from
most forms of sheep scrapie.13 Similarly vCJD can be distin-
guished from other human prion diseases, in particular sporadic
CJD (sCJD),14,15 whereas BSE and vCJD share both mobility
type and have a similar glycoform ratio.14 This BSE/vCJD PrPres
type (referred to a type 2B or type 4) appears to be closely associ-
ated with the agent since (1) it also characterizes the PrPres that
accumulates in peripheral tissues in clinical vCJD,16 (2) it is
maintained following secondary transmission of vCJD by blood
transfusion both in the brain of clinical cases,17 and in the spleen
of asymptomatic or preclinical individuals,18,19 (3) it is largely
stable on transmission to wild-type and humanised transgenic
mice12,20 and (4) it is maintained in cell-free conversion systems
in which either BSE or vCJD brain homogenates are used to seed
conversion of normal human prion protein.21
While type 2B PrPres provides a convenient additional diag-
nostic tool for human BSE identification,22 it does not provide a
complete description of PrPSc in cases of vCJD, nor does it pro-
vide a biochemical definition of the agent. The largest amount of
PrPSc in the vCJD brain is actually protease sensitive23 and there-
fore does not figure in conventional PrPres typing. Even within
the protease-resistant fraction of vCJD PrPSc there is evidence of
a minority PrPres type.24 The use of assays that do not depend
upon protease-resistance as a definition of PrPSc show that aggre-
gation state and stability are additional biochemical parameters
that may be relevant to neurotoxicity and agent replication.25,26
vCJD in the UK and Beyond
Since the first recorded case of vCJD in 1996, 177 cases of
definite or probable vCJD have been reported in the UK (as of
April 2014). The annual number of deaths reached a peak in
2000 with 28 deaths but since 2006, deaths from vCJD have lev-
elled off at 2–5 per year with none reported in 2012 and only
one in 201327 (Fig. 3). Originally restricted to the UK, 51 cases
have now been reported in 11 other countries with a worldwide
Figure 1. Vacuolation scoring in the mouse brain. Lesion proﬁle compari-
son of vCJD and BSE following transmission to RIII mice. Data shows
mean lesion proﬁle § standard error of the mean (n  6). G1-G9, gray
matter scoring regions; (G1) dorsal medulla, (G2) cerebellar cortex, (G3)
superior colliculus, (G4) hypothalamus, (G5) thalamus, (G6) hippocam-
pus, (G7) septum, (G8) retrosplenial and adjacent motor cortex, (G9) cin-
gulate and adjacent motor cortex.
Figure 2. Abnormal PrP deposition in hippocampus of RIII and VM mice
following inoculation with BSE or vCJD. (A) BSE in RIII mouse; (B) vCJD in
RIII mouse; (C) BSE in VM mouse; (D) vCJD in VM mouse (bar, 100 mm;
anti-PrP antibody: 6H4).
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total of 228 (Fig. 3). Outside of the UK, most cases have
occurred in France (27 cases to date) and are thought to be
related to the peak in volume of beef imports originating from
the UK during 1985–1995.28 This potential relationship is
shown in the peak in number of deaths from vCJD in France in
2005, 5 y after a similar peak in the UK.28,29 Further evidence of
the link between UK and French vCJD has arisen from compara-
tive studies comparing epidemiologic, clinical, pathological, and
biochemical analyses of vCJD cases from both countries indicat-
ing that the same strain of agent could be responsible.30 The type
2B PrPres that characterizes UK vCJD cases15 is also present in
vCJD patients from France30 and cases from Holland, Portugal,
Spain, and Italy (Head and Ironside, unpublished information),
consistent with the same strain of agent being involved in these
different countries.
Exports of UK meat or cattle are assumed to have played a
major role in the incidence of vCJD cases in other countries;31
however there is the possibility that indigenous BSE or another
strain of agent is responsible. In order to assess whether the same
strain of agent is responsible for all vCJD cases worldwide, Diack
et al.32 performed strain typing of French, Italian, Dutch, and
American cases of vCJD. These were all of the 129MM genotype
and with limited exposure to UK BSE. Analysis of the transmis-
sion properties showed that the non-UK cases shared the same
characteristics as UK cases of vCJD, however small differences
were apparent in the incubation period rankings which are cur-
rently being studied.32 The similar characteristics between UK
and non-UK cases of vCJD suggest that current diagnostic crite-
ria are sufficient to detect cases in all countries at this time. How-
ever these studies characterized “typical” cases of vCJD and do
not take into account atypical cases or those occurring in geno-
types other than 129MM.
All Codon 129 Genotypes are Susceptible to vCJD
Mutations and polymorphisms in the prion protein gene
(PRNP) can influence or be associated with disease, i.e.,
E200K-129M in genetic CJD or A117V-129V in Gerstman–
Str€aussler–Scheinker disease (GSS). The codon 129 polymorphism
(methionine (M)-valine (V)) of PRNP is known to be associated
with susceptibility to CJD33 with evidence from studies of kuru
suggesting that heterozygosity is associated with increased survival
times.34 As stated, all definite and probable cases of clinical vCJD
have been of the 129MM genotype which is in contrast to the
normal distribution of genotypes in the general UK population;
42% 129MM, 47% 129MV, and 11% 129VV35 and is suggestive
of an association between vCJD susceptibility and genotype.
Experimental transmission studies have utilized gene targeted
mice expressing human PrPC at physiological levels and overex-
pression models carrying each of the codon 129 genotypes to
reveal that human-to-human transmission of vCJD is possible and
that all genotypes have the potential to be affected.9,20,36 Bishop
et al.20 used gene targeted models allowing direct comparison
between mouse lines; these studies showed that transmission effi-
ciency varied in the order MM > MV > VV with different path-
ological characteristics for each genotype. Mice expressing
129MM (HuMM) showed the greatest transmission efficiency
and the earliest onset of both clinical disease and TSE related
pathology. Although fewer HuMV mice were clinically affected
and showed an extended incubation period, similar numbers dem-
onstrated evidence of PrPSc compared with HuMM mice. In con-
trast only one HuVV mouse showed evidence of PrPSc.20 This
pattern of susceptibility has been repeated in a series of vCJD
transmissions both from UK and non-UK material. This data sug-
gests that in humans not only do all genotypes have the potential
to be affected but that the different genotypes may manifest dis-
ease in different ways and indeed 129MV and 129VV individuals
may have long asymptomatic incubation periods.
The evidence from the mouse studies has been shown in
humans by the discovery of PrPSc in an asymptomatic PrP codon
129 heterozygote individual who died of a non-neurological dis-
order 5 y after receiving blood from an individual who later went
onto develop clinical vCJD. In this individual evidence of PrPSc
was found in the spleen and a cervical lymph node.19 Transmis-
sion studies have now shown the spleen from this individual to
be infectious.37 A possible case of vCJD in a 129MV individual
was reported in 2009, however vCJD was not confirmed since no
autopsy was undertaken.38 Additionally, retrospective studies of
anonymised tonsil and appendix samples have shown evidence of
PrPSc in all 3 genotypes giving further support to the evidence
that all genotypes are susceptible to vCJD.39,40
Modeling human genetic susceptibility to BSE using cell-free
assays confirms the importance of methionine at codon 129 of
the PRNP gene as a susceptibility factor, and shows the conver-
sion efficiency to be MM > MV > VV, irrespective of whether
the brain homogenate used to seed the reaction is vCJD, cattle
BSE or experimental sheep BSE.21
Blood as a Route of Transmission of vCJD
The UK shows the highest incidence of vCJD in the world.27
At early stages of the epidemic, it was largely accepted that there
was a minimal risk of transmission of vCJD from donations of
Figure 3. Reported incidence of vCJD deaths in the UK and in non-UK
countries.
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peripheral blood/tissue from affected individuals to others via iat-
rogenic routes. That said great efforts were made to trace and
track the fate of blood components used for transfusion from
donors known to have vCJD.41 Concomitantly, the likelihood of
transmission of prion infection through blood, either by inocula-
tion or transfusion and the distribution of prion-associated infec-
tivity in blood components was being assessed using a range of
animal models, typically small animal models.42-48 These pro-
duced estimates of »10 infectious doses (ID)/ml in hamster
blood.47,49 Rodent models do not however represent accurately
the procedures used in a clinical setting for blood transfusion.
Large animal models such as sheep or deer infected with BSE or
scrapie provide a suitable alternative to better assess the likelihood
of transmission of prion disease following exposure by blood
transfusion.50-52 Larger volumes of blood can be collected from
such animals and processed into components with similar specifi-
cations as those used for transfusion to humans.53 Furthermore
the peripheral pathogenesis of scrapie and BSE in sheep closely
resembles that of humans affected with vCJD.54,55 Over a decade
ago, transfusion studies in sheep first demonstrated that all clini-
cally-relevant blood components collected at both preclinical and
clinical time points contained sufficient titers of disease-associ-
ated infectivity and could be transmitted to recipients after a sin-
gle transfusion event. Moreover, the number of recipients that
developed disease was suggestive that blood transfusion was a
highly efficient route by which prion diseases could be transmit-
ted.56 Of note, in this and other studies, was the finding that the
process of leucoreduction alone did not prevent the transmission
of prion disease following blood transfusion.49,53 The relevance
of the latter point being that all components used for blood trans-
fusion in humans are subject to universal leucoreduction. Data
showing that blood from prion-infected animals was infectious
was confirmed by other research groups using sheep57,58 and deer
blood transfusion models.59-61
Since the late 1990s a number of risk reduction strategies were
implemented to safeguard the UK blood (and blood product)
supply. This included donor deferral and exclusion, importation
of plasma from the USA for the preparation of plasma deriva-
tives, i.e., clotting factors; the use of disposal instruments for cer-
tain surgical and dental procedures; and universal leucoreduction
of all components used for transfusion.62 Following a further risk
assessment initiated by the Department of Health, selected
groups of patients were informed that they could be considered
to have a “small increased risk of carrying the vCJD agent” fol-
lowing receipt of certain batches of plasma products. These
groups included hemophiliacs and those affected with other
bleeding disorders and those with primary or secondary
immunodeficiencies.62,63
It was not until 2004 that blood from vCJD-infected humans
was shown to pose a significant risk of acquiring prion infection.
This followed the identification of 2 potential cases of blood-trans-
fusion acquired vCJD.19,64 A few years later saw the identification
of another case of apparent transfusion-acquired vCJD.65 These
data were collated and cases presented in detail in 2006.41,66 A
fourth occurrence of transfusion-acquired vCJD was subsequently
identified and all cases have been summarized in a recent review.67
The 4 affected individuals were from the UK and all received
non-leucoreduced red cell concentrates from UK donors, who
were asymptomatic of infection at the time of donation but later
died from vCJD. The transfusions took place between 1996 and
1999. Of the 4 transfusion recipients, 3 developed a clinical infec-
tion consistent with previously identified cases of vCJD (i.e., dis-
eased-associated prion protein was evident in brain and peripheral
lymphoid tissues examined post-mortem).17 These individuals
were identified as being methionine homozygous at codon 129 in
the PRNP gene. The remaining transfusion recipient showed no
clinical signs associated with vCJD or other neurological-type con-
ditions and there was no evidence of disease-associated prion pro-
tein in the individual’s brain and indeed the patient died of causes
unrelated to vCJD.19 Disease-associated prion protein was identi-
fied in selected lymphoid tissues such as the spleen and a cervical
lymph node. Unlike the 3 clinical cases previously reported, this
recipient was identified as having a different PRNP genotype being
heterozygous (MV) at codon 129.
A surveillance program (established by the National CJD
Research and Surveillance Unit and the UK Hemophilia Centre
Doctors Organisation) identified the first case of vCJD infection
in a hemophiliac patient.18,68,69 The study examined biopsy and
autopsy samples of lymphoid or brain tissue from a small num-
bers of samples submitted for investigation. The individual was
an elderly male who resided in the UK. In conjunction with sur-
gical procedures, the patient received numerous units of non-leu-
coreduced red cells and thousands of units of Factor VIII. The
factor VIII was prepared from UK plasma pools and it was found
that some of the pooled-plasma could be traced back to a donor
who died from vCJD. The individual showed no signs of vCJD
or other neurological conditions and was MV at codon 129 in
the PRNP gene. Upon repeated examination, a specific area of
spleen was positive for the abnormal form of the prion protein. A
subsequent risk assessment found that of all possible sources of
vCJD infection, including dietary exposure, the mostly likely was
determined as treatment with UK-sourced clotting factors.70 To
date, there have been no further cases of vCJD acquired following
the transfusion of blood, blood components or clotting factors.
While there has been no documented evidence, to date, of the
transmission of sCJD infection following blood transfusion in
humans,41 a recent, though limited study, has reported the pres-
ence of disease-associated infectivity in plasma obtained from 2
patients affected with sCJD.71
Although estimates of the infectious titer of blood from
patients with vCJD are low71,72 it has been demonstrated
that blood and components from asymptomatic individuals
appear capable of transmitting vCJD-infection following
blood transfusion. Major efforts have been made toward the
development of screening assays and diagnostic tests for
vCJD in blood72-75; the development and implementation of
prion reduction filters76-80; understanding the numbers of
individuals who may be sub-clinically affected with
vCJD39,81-84 and what this really means in terms of further
spread of vCJD. There are significant challenges to be faced
in each of these areas, which are further confounded by the
absence of an available treatment for vCJD.
www.landesbioscience.com 289Prion
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Prevalence of Asymptomatic vCJD Infection
The UK population had a wide exposure to the BSE agent
through contaminated meat products in the food chain in the
1980s and early 1990s, resulting in 177 definite cases of vCJD to
date. Of the cases genotyped, all were methionine homozygotes
at codon 129 in the PRNP gene. However there are ongoing con-
cerns over vCJD infection in other codon 129 genotypes with
potentially longer incubation periods. This has prompted a series
of tissue–based studies on the prevalence of vCJD infection in
lymphoid tissues (appendices and tonsils) removed surgically as
part of treatment for appendicitis, tonsillitis, and related disor-
ders in otherwise healthy individuals with no neurological symp-
toms. Variant CJD differs from other human prion diseases in
the widespread involvement of lymphoid tissues by the causative
agent which is detectable in follicular dendritic cells and is associ-
ated with infectivity.16,85
Review of paraffin-embedded appendices that had been
resected from a small number of individuals before the onset
of vCJD revealed that prion protein was detectable in the lym-
phoid follicles in the wall of the appendix for at least 2 y prior
to the onset of vCJD symptoms.86 This observation allowed
the possibility of a large-scale retrospective survey of appendix
and tonsil tissues from histopathology departments across the
UK to determine the extent of asymptomatic vCJD infection
as revealed by immunohistochemistry on paraffin-embedded
tissues. These studies have proven challenging in terms of
logistics and ethics and have proceeded on the basis of using
anonymised specimens that are not directly linkable to any
individual. The first of these studies reported in 2004 an esti-
mated prevalence of asymptomatic vCJD infection in 237 per
million in 4000 individuals in the UK (3 in 12 674 positive
specimens tested), but with very wide 95% confidence inter-
vals (49–692 per million).83 Two subsequent prospective stud-
ies on tonsil tissues collected frozen tissue samples as well as
paraffin-embedded tissues, which allowed the use of enzyme
immunoassays and western blotting in addition to immunohis-
tochemistry for the detection of the abnormal prion pro-
tein.81,82,87 No positives were detected in the frozen tissue
samples from either study (2000 in Frosh et al.87; 32 661 in
Clewley et al,81). Immunohistochemistry was subsequently
performed on 10 075 samples from the de Marco et al.82
study, with 1 apparent positive detected.
In order to resolve the findings from these studies, a larger
unlinked and anonymised immunohistochemical survey was per-
formed on archived paraffin-embedded appendix samples from
41 histopathology departments in the UK.39 Of the 32 441 sam-
ples assessed, 16 were positive for abnormal prion protein, giving
an overall prevalence of 493 per million (95% confidence inter-
vals 282–801 per million), which is broadly in keeping with the
results of the earlier study by Hilton et al.83 PRNP codon 129
genotype analysis of the positive cases showed that all possible
genotypes were involved, with a predominance of the valine
homozygous genotype,39 as for the Hilton et al. study,40 and in
contrast with the definite cases of vCJD identified to date. These
findings have a wide range of implications, including the need
for continuing surveillance of human prion diseases in the UK
and the risks of secondary vCJD transmission from asymptom-
atic infected individuals via surgical instruments or blood trans-
fusion; the latter is now the subject of a UK Parliamentary
Inquiry (Parliamentary Select Committee on Science and Tech-
nology, 201388).
Diagnostics and Treatment
The diagnosis of vCJD rests on recognizing the typical pheno-
type and applying appropriate specialist investigations, in partic-
ular MRI brain scan (Fig. 4). The clinical features are
remarkably stereotyped. There is an initial phase of around 6 mo
dominated by psychiatric symptoms, including depression, delu-
sions, and anxiety89 followed by the rapid development of neuro-
logical features,90 typically confusion, ataxia, and involuntary
movements, which may be choreiform, dystonic, or myoclonic.
The duration of illness from onset to death averages 14 mo91 in
contrast to sCJD in which the mean survival is 4 mo.
The electroencephalogram does not show the periodic sharp
wave complexes that are seen in sCJD, except rarely in the termi-
nal stages of the illness92 and the CSF 14–3-3 immunoassay is
only positive in about half the cases.93 The CSF RT-QuIC has
been negative in vCJD in all assays to date. The most helpful
investigation is MRI brain scan, which shows high signal in the
pulvinar region of the thalamus, the so-called hockey stick sign,
on FLAIR (Fig. 4) and DWI sequences in over 90% of cases.94
Figure 4. MRI brain scan in variant CJD. FLAIR axial section at the level of
the basal ganglia showing bilateral symmetrical dorsomedial and pulvi-
nar thalamic hyperintensity. Courtesy of Dr David Summers.
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Tonsil biopsy shows immunostaining and deposition of type 2B
or type 4 PrPres in the majority of cases,95,96 but this test is inva-
sive, and definitive diagnosis rests on neuropathological examina-
tion of brain tissue, usually at post-mortem.
Highly sensitive and specific diagnostic criteria, including a
combination of core clinical features and the results of MRI brain
scan and pathology, have been formulated97 and validated.98
Cases classified as definite or probable are reported by interna-
tional surveillance systems as the likelihood of accurate diagnosis
in possible cases is uncertain.
The phenotype in cases of vCJD in an MV or VV genetic
background cannot be predicted and continued vigilance is nec-
essary in order to identify such cases.
Treatment of vCJD has been attempted using a range of med-
ications, but none have been proven to be effective. Initial reports
of improvement following treatment with quinacrine have not
been confirmed in observational trials99,100 and this drug is no
longer used in vCJD treatment. Studies in animal models raised
the possibility that pentosan polysulphate (PPS) might be a can-
didate treatment for vCJD101 and extended survival has been
reported in a small number of treated cases.102,103 However, this
medication has to be given by intraventricular infusion, requiring
a neurosurgical procedure, and treated patients continued to
decline with no reversal of severe neurological deficits.104 Post-
mortem examination of one case of vCJD treated with PPS
showed extensive and severe pathology.105 Some cases of vCJD
received doxycycline with no obvious benefit and a controlled
trial in sCJD has not demonstrated efficacy.99
Emergence of Novel Strains
Identification of novel strains involves veterinary and medical
vigilance, but it also requires a proper and full characterization of
known prion agents. While the deployment of wild-type mouse
panels, transgenic mice, and non-human primates all rapidly
concluded that vCJD was a novel human prion strain related to
BSE (see above), determining how many distinct human prion
strains there are has proved surprisingly difficult, especially for
sCJD. Transmission studies in humanised transgenic mice and
non-human primates point to 4 major groups within sporadic,
iatrogenic CJD, Kuru, and some genetic CJD cases, termed M1,
V1, M2, and V2.22,106 Sporadic fatal insomnia and fatal familial
insomnia (FFI) together may represent a sixth strain107 and 2 fur-
ther transmissible phenotypes can be derived from GSS disease:
one involving a transmissible amyloid phenotype, the other a
fully transmissible spongiform encephalopathy.108,109 The trans-
mission properties of PrP cerebral amyloid angiopathy and Vari-
ably ProteaseSensitive Prionopathy (VPSPr) remain to be
reported. The relationship between human disease phenotypes,
agent strain, and prion biochemistry is further complicated by
the now widely recognized phenomenon of distinct PrPres type
co-occurrence in the sCJD, vCJD and VPSPr brain.15,24,110
Surveillance for BSE in cattle, sheep, and goats has identified
new (or newly discovered) animal prion diseases including atypical
scrapie in sheep and so called H- and L-type BSE in cattle. These
along with chronic wasting disease (CWD) in deer and elk
represent a potential zoonotic risk to human health that is hard to
quantify. While Wilson et al.111 have shown no transmission of
CWD, BASE, H-type BSE, and atypical scrapie to mice express-
ing wild-type levels of human PrP, Kong et al.112 demonstrated
transmission of BASE to an alternative line of mice expressing
wild-type levels of human PrP. In contrast, Beringue et al.113
showed transmission of BASE to mice overexpressing human PrP
but no evidence of H-type BSE transmission, furthermore no evi-
dence of CWD transmission to overexpressing mice has been
identified.114,115 This difference in transmission results may be
due to different genetic backgrounds or differences in PrP expres-
sion levels between the different mouse lines. An alternative to
modeling the species barrier is the cell-free conversion assay which
points to CWD as the animal prion disease with the greatest
zoonotic potential, after (and very much less than) BSE.116
Surveillance
Continued surveillance for long-term effects of BSE exposure
in the UK human population appears necessary for the foresee-
able future in order to discount possible second wave epidemics
that might depend on genetic susceptibility, subclinical infection,
and secondary transmission or disease in defined “at risk” patient
groups such as hemophiliacs or patient groups in which full
ascertainment is difficult, such as the elderly.
However, an additional concern is associated with idiopathic
human prion disease. Sporadic CJD is not a uniform condition and
the phenotype is clearly influenced by the codon 129 genotype of
the patient and the prion protein type that accumulates in their
brain. The etiological basis of the condition might be presumed to
be spontaneously occurring, but this is not known with certainty in
general, or in individual specific cases. Neither are the molecular
mechanisms of spontaneous conversion of the prion protein to its
pathogenic form well understood or easily investigated. Addition-
ally, surveillance identifies apparently sporadic cases of human
prion disease that do not fit well into currently accepted classifica-
tion systems. This is exemplified by the recent identification of a
new human prion disease (VPSPr by Gambetti et al.117) and its
prospective and retrospective identification in other countries subse-
quently.118,110 The true prevalence, the relationship to sCJD and
the risk to public health of VPSPr are yet to be determined.
Conclusions
Since the identification of vCJD we have made progress in
identifying routes of infection, controlling further infection, pro-
ducing models of disease, developing decontamination proce-
dures, and understanding susceptibility to disease. The vCJD
epidemic in the UK now appears to be in decline and it appears
that the control measures in food production and blood supplies
have prevented further vCJD cases arising through dietary/
infected blood exposure.
Despite this, there are still ongoing concerns over cases of
vCJD arising in countries where little or no exposure to UK meat
products have occurred, the presence of subclinical vCJD in the
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UK population with the possibility of further human-to-
human transmission and the identification of new strains of
human prion disease. These scenarios necessitate ongoing
studies in understanding transmission properties, disease diag-
nosis, and therapeutics. The identification of novel human
prion diseases and the current estimates of subclinical vCJD
infections show the importance of continued CJD surveil-
lance and maintaining control measures already in place to
protect human health.
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